Glassman Wealth Services’s BridgeBio Pharma BBIO Stock Holding History

Glassman Wealth Services’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-15	Closed	-$606	–	374
2023 Q4	$606	Hold	15	–	–	﹤0.01%	1680
2023 Q3	$396	Sell	15 -12	-44%	-$341	﹤0.01%	1783
2023 Q2	$464	Hold	27	–	–	﹤0.01%	1654
2023 Q1	$448	Buy	+27	New	+$315	﹤0.01%	1637
2022 Q2	–	Sell	-100	Closed	-$1K	–	1672
2022 Q1	$1K	Buy	+100	New	+$1.03K	﹤0.01%	1329
2020 Q1	–	Sell	-8	Closed	–	–	1139
2019 Q4	$0	Buy	+8	New	+$222	﹤0.01%	1183

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Glassman Wealth Services's BBIO Position: Q1 2024 in Review

Glassman Wealth Services sold out of BridgeBio Pharma (BBIO) in Q1 2024, closing a stake of 15 shares — an estimated $606 sold.

Glassman Wealth Services first reported a position in BBIO in Q4 2019 and held it in 6 quarters. The position peaked at $1K in Q1 2022. 244 funds tracked by Wall St. Rank hold BBIO as of Q1 2024.

Glassman Wealth Services reported no remaining BridgeBio Pharma position as of Q1 2024 after selling out during the quarter.
Glassman Wealth Services sold 15 BridgeBio Pharma shares in Q1 2024, an estimated $606.
Glassman Wealth Services first reported a position in BridgeBio Pharma in Q4 2019 and held it in 6 quarters.
Glassman Wealth Services's BridgeBio Pharma position peaked at $1K in Q1 2022.
244 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2024.

Based on Glassman Wealth Services's 13F filing for Q1 2024, filed 3 May 2024.